OOIR: Observatory of International Research

Papers

(The H4-Index of npj Parkinsons Disease is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease	231
Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism	139
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	133
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein	132
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease	123
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease	104
Differences in brain aging between sexes in Parkinson’s disease	104
Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson’s disease	102
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome	102
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective	98
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease	95
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances	95
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease	90
Investigating the ageing-Parkinson’s disease nexus: standardisation of in vitro models and techniques by the PD-AGE network	85
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI	80
Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease	78
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions	74
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders	70
A versatile computational algorithm for time-series data analysis and machine-learning models	67
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	67
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease	67
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study	66
Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population	66
Redefining the hypotheses driving Parkinson’s diseases research	65
Direct disassembly of α-syn preformed fibrils into α-syn monomers by an all-D-peptide	64

Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research	63
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD	62
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	61
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease	60
α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission	60
The experience of Anxiety for people with Parkinson’s disease	60
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease	57
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings	57
The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model	56
Advanced brain aging in Parkinson’s disease with cognitive impairment	56
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies	56
Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism	55
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	55
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia	53
Lrrk2 G2019S mutation incites increased cell-intrinsic neutrophil effector functions and intestinal inflammation in a model of infectious colitis	53
Baseline [18F]FP-CIT PET-based deep learning prediction of levodopa-induced dyskinesia in Parkinson’s disease	53
Association of the number of minor hallucinations and well-structured visual hallucinations in Parkinson’s disease	52
Functional network differences between unilateral and bilateral deep brain stimulation of the subthalamic nucleus	51
Resting and action tremor in Parkinson’s disease: pathophysiological insights from long-term STN-DBS	49
Synuclein phosphorylation: pathogenic or physiologic?	48
Enrichment of gut-derived metabolites in a Parkinson’s disease subtype with REM sleep behavior disorder	47
Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism	47
Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?	47